Song Lin, Liu Fang, Liu Yao, Zhang Ruoqi, Ji Huanhuan, Jia Yuntao
Children's Hospital of Chongqing Medical University, Pharmacy Department, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, No.136, Section 2, Zhongshan Road, Chongqing, China, 400014.
First Affiliated Hospital of Third Military Medical University (Army Medical University), Pharmacy Department, 30 Gaotanyan Street, Shapingba District, Chongqing, China, 400038.
Cochrane Database Syst Rev. 2020 Apr 20;4(4):CD012253. doi: 10.1002/14651858.CD012253.pub3.
This is an updated version of the original Cochrane Review published in 2018, Issue 5. Epilepsy affects over 70 million people worldwide, and nearly a quarter of patients with seizures have drug-resistant epilepsy. People with drug-resistant epilepsy have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life.
To assess the efficacy and tolerability of clonazepam when used as an add-on therapy for adults and children with drug-resistant focal onset or generalised onset epileptic seizures, when compared with placebo or another antiepileptic agent.
For the latest update we searched the following databases on 4 June 2019: Cochrane Register of Studies (CRS Web), MEDLINE (Ovid) 1946 to 3 June, 2019. The Cochrane Register of Studies (CRS Web) includes the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), and randomised or quasi-randomised, controlled trials from Embase, ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform (ICTRP).
Double-blind randomised controlled studies of add-on clonazepam in people with resistant focal or generalised onset seizures, with a minimum treatment period of eight weeks. The studies could be of parallel or cross-over design.
Two review authors independently selected studies for inclusion, extracted relevant data, and assessed trial quality. We contacted study authors for additional information.
We found no double-blind randomised controlled trials which met the inclusion criteria.
AUTHORS' CONCLUSIONS: There is no evidence from double-blind randomised controlled trials for or against the use of clonazepam as an add-on therapy for adults and children with drug-resistant focal or generalised onset epileptic seizures. Since the last version of this review no new studies have been found.
这是2018年第5期发表的原始Cochrane系统评价的更新版本。癫痫影响全球超过7000万人，近四分之一的癫痫发作患者患有药物难治性癫痫。药物难治性癫痫患者过早死亡、受伤、心理社会功能障碍的风险增加，生活质量下降。
评估氯硝西泮作为附加疗法用于治疗成人和儿童药物难治性局灶性发作或全身性发作癫痫时，与安慰剂或另一种抗癫痫药物相比的疗效和耐受性。
为进行最新更新，我们于2019年6月4日检索了以下数据库：Cochrane研究注册库（CRS网络版）、MEDLINE（Ovid）1946年至2019年6月3日。Cochrane研究注册库（CRS网络版）包括Cochrane癫痫小组专业注册库、Cochrane对照试验中心注册库（CENTRAL）以及来自Embase、ClinicalTrials.gov和世界卫生组织国际临床试验注册平台（ICTRP）的随机或半随机对照试验。
氯硝西泮作为附加疗法用于治疗耐药性局灶性或全身性发作患者的双盲随机对照研究，最短治疗期为8周。研究可以是平行设计或交叉设计。
两位综述作者独立选择纳入研究、提取相关数据并评估试验质量。我们联系研究作者以获取更多信息。
我们未找到符合纳入标准的双盲随机对照试验。
双盲随机对照试验没有证据支持或反对使用氯硝西泮作为附加疗法治疗成人和儿童药物难治性局灶性或全身性发作癫痫。自本综述的上一版本以来，未发现新的研究。
